Literature DB >> 859644

Irreversible binding of 3-14C-antipyrine to hepatic protein in vivo and in metabolizing liver microsomes.

S Tabarelli-Poplawski, H Uehleke.   

Abstract

After i.p. injection of 3-14C-antipyrine (10 micronmole = 1.9 mg with 10 micronCi per 10 g of body weight) to mice radioactivity was irreversibly bound to liver proteins. The irreversible binding reached maximal values of 0.15 nmole/mg protein in liver microsomes after 30-60 min. During 60 min incubation with liver microsomes of mice and rabbits (phenobarbital pretreated) and a NAKPH-regenerating system 3-14C-antipyrine was irreversibly bound to microsomal protein at a rate of 1.5 nmole/mg protein (mouse) and 3 nmole/mg protein (rabbit). In identical incubates with rabbit liver microsomes the 4-hydroxylation of antipyrine was 24 nmole/mg protein in 60 min and formaldehyde production from antipyrine 3 nmole/mg protein in 60 min. In incubates with rabbit liver microsomes the binding rate was 80-90% inhibited by 1mM metyrapone, SKF 525-A and trichloropropene epoxide respectively; 4-hydroxylation was 70-80% inhibited by the same substances. In the presence of 1mM GSH, cysteine or ethylene diamine binding was 30-40% inhibited, whereas 4-hydroxylation showed no inhibition.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 859644     DOI: 10.1007/BF00508817

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  24 in total

1.  [PYRAMIDON AGRANULOCYTOSIS. AN IMMUNOHEMATOLOGICAL STUDY].

Authors:  S THIERFELDER; C MAGIS; M SAINT-PAUL; J DAUSSET
Journal:  Dtsch Med Wochenschr       Date:  1964-03-13       Impact factor: 0.628

2.  [Metabolic products of amino-pyrine and related compounds in humans].

Authors:  J HALBERKANN; F FRETWURST
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1950-03

3.  The fate of aminopyrine (pyramidon) in man and methods for the estimation of aminopyrine and its metabolites in biological material.

Authors:  B B BRODIE; J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1950-06       Impact factor: 4.030

Review 4.  Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds.

Authors:  F Oesch
Journal:  Xenobiotica       Date:  1973-05       Impact factor: 1.908

5.  Arene oxides and the NIH shift: the metabolism, toxicity and carcinogenicity of aromatic compounds.

Authors:  J W Daly; D M Jerina; B Witkop
Journal:  Experientia       Date:  1972-10-15

6.  [Binding of carbon tetrachloride to reduced microsomal cytochrome P-450 and to heme].

Authors:  O Reiner; H Uehleke
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1971-08

7.  Irreversible binding of ethynyl-estradiol metabolites to protein and nucleic acids as catalyzed by rat liver microsomes and mushroom tyrosinase.

Authors:  H M Bolt; H Kappus
Journal:  J Steroid Biochem       Date:  1974-04       Impact factor: 4.292

8.  Binding of 14 C-carbon tetrachloride to microsomal proteins in vitro and formation of CHC1 3 by reduced liver microsomes.

Authors:  H Uehleke; K H Hellmer; S Tabarelli
Journal:  Xenobiotica       Date:  1973-01       Impact factor: 1.908

9.  Norphenazone, a new metabolite of phenazone in human urine.

Authors:  J D Baty; D A Evans
Journal:  J Pharm Pharmacol       Date:  1973-01       Impact factor: 3.765

10.  [Demonstration of a new reactive metabolite in metabolism of phenazone (antipyrine)].

Authors:  G Wittemann; R Schüppel
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1968
View more
  2 in total

1.  Enhancement of antipyrine clearance and induction of antipyrine 4-hydroxylation by 3-methylcholanthrene in rats [proceedings].

Authors:  M A Kroos-De Haan; J Noordhoek
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

2.  Trichloroethylene vapours do not produce dominant lethal mutations in male mice.

Authors:  R Slacik-Erben; R Roll; G Franke; H Uehleke
Journal:  Arch Toxicol       Date:  1980-05       Impact factor: 5.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.